Basic Trading Data for Nektar Therapeutics (NKTR)

In the past 52-week period, shares of Nektar Therapeutics (NASDAQ:NKTR) have moved within the range of $11.41 to $61.88. On the stock’s most recent trading day, the company’s shares ended the regular session at $57.65, which is 6.84% lower than its 52-week high.

Nektar Therapeutics (NKTR) has demonstrated a 20-day simple moving average (SMA) of 2.98%, and a 50-day SMA of 32.71%. This public company’s current market capitalization stands at $9.20 billion.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Measuring Wall Street analysts’ average enthusiasm for a specific stock is critical when considering a potential investment. According to the latest data, the consensus recommendation for Nektar Therapeutics (NKTR) is Outperform.

Publicly-traded companies normally report earnings and revenue figures that are either above or below the average Wall Street projection. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Nektar Therapeutics (NKTR) delivered a 30.35% surprise with its net revenue. Sales reached $0.15 billion during the three-month period, compared to the average analyst estimate of $0.12 billion.

Ownership at Nektar Therapeutics (NKTR), According to Most Recent SEC Filings

We can gain important insight by taking a look at institutional ownership, as detailed in public companies’ latest 13F filings. Nektar Therapeutics (NKTR) has 0 billion shares outstanding currently, 97.21% of which belong to institutional investors. Those institutional holdings amount to $9.14 billion.

Additionally, according to the most recent 13F filing from Nektar Therapeutics (NKTR), there were 24 new positions totaling 2,208,073 shares of the company’s stock. There were 15 sold out positions, on the other hand, totaling 1,185,979 shares.

Short, Medium and Long Term Indicators

Analyzing the average trade volume of a publicly-traded company’s stock – in the short, medium and long terms – is helpful for gaining insight into trading activity and general investor sentiment. Nektar Therapeutics (NKTR) has had a 20-day average volume of 1,951,365 shares, with an average of 40% of short term indicators pointed at Buy.

The stock’s 50-day average volume has been 2,595,056 shares, with an average of 25% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 1,861,127 shares with 67% of long-term indicators pointing to Buy.